Beijing 302 Hospital

This study tests whether adding the HIV drug rilpivirine to standard treatment can help people with HIV whose immune systems haven't fully recovered. About 21 adults with low CD4 counts despite years of successful viral suppression will receive rilpivirine for 48 weeks. The goal …

This study tests a combination of five drugs (venetoclax, azacitidine, cytarabine, idarubicin, and G-CSF) as a first treatment for adults aged 18-70 with acute myeloid leukemia (AML) who are healthy enough for strong chemotherapy. The goal is to see how many patients achieve comp…

This early-phase study tests whether giving chemotherapy followed by an infusion of immune cells from a partially matched donor can help patients with relapsed or refractory leukemia get to a stem cell transplant. Only 5 participants will be enrolled to check safety and side effe…

This phase 2 trial tests a combination of venetoclax (a targeted drug), standard chemotherapy (azacitidine or decitabine), and an infusion of immune cells from a partially matched donor for people with intermediate- or high-risk myelodysplastic syndromes (MDS) who cannot or choos…